ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Regeneron Pharmaceuticals clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 413 studies whose lead sponsor is Regeneron Pharmaceuticals or the company grouped under it. 83 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Regeneron Pharmaceuticals with Bristol-Myers Squibb and Johnson & Johnson →

Pipeline: 43 programs

Each counted once: 43 with a study Regeneron Pharmaceuticals leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 15 with the most live studies.

Program
cemiplimabPhase 3 · 16 live · Carcinoma, Non-Small-Cell Lung · primary completion Mar 2027☆ Track
cenvacibartPhase 3 · 11 live · Venous Thromboembolism · primary completion Feb 2027☆ Track
fianlimabPhase 3 · 9 live · Melanoma · primary completion Jan 2027☆ Track
odronextamabPhase 3 · 6 live · Lymphoma, B-Cell · primary completion Feb 2028☆ Track
amrecibartPhase 3 · 4 live · Venous Thromboembolism · primary completion Feb 2027☆ Track

10 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Regeneron Pharmaceuticals’ own registered studies; Regeneron Pharmaceuticals’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

One of Regeneron Pharmaceuticals’ programs has a dated deal behind it: 1 brought in. Each from the companies’ own releases and filings, linked; the registry does not record them.

Brought in 1

What it is testing

The drugs Regeneron Pharmaceuticals’ studies test, most open studies first — 48 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 48; every drug is on its own page, and each page lists its sponsors.

Coming up

30 of Regeneron Pharmaceuticals’ studies under way reach primary completion within a year, 6 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 3D
  3. 1J’27
  4. 4F
  5. 5M
  6. 3A
  7. 2M
  8. 2J
  9. 1J
  10. 3A
  11. 2S
  12. 1O
  13. 2N

The 12 nearest

Show 7 more

Add all 30 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 413 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now8320%Recruiting 69 · Not yet recruiting 14
  • Under way, not recruiting4010%
  • Completed21452%
  • Stopped early5814%Terminated 45 · Withdrawn 13
  • Status unknown or other184%Approved for marketing 7 · Available 7 · No longer available 4

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 5226

By the year each study started; 10 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Regeneron Pharmaceuticals.

  • Regeneron Pharmaceuticals
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    412 studies
  • Decibel Therapeutics
    Acquired — became part of Regeneron Pharmaceuticals, Sep 25, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Regeneron Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 413. Browse all 413 →